In the first-line treatment of metastatic GC, five pivotal phase III trials, CheckMate 649, ATTRACTION-4, ORIENT-16, RATIONALE305, and KEYNOTE-859, showed that the combination of ICIs with chemotherapy significantly prolonged PFS and/or OS compared to chemotherapy alone in patients with positive or high PD-L1 expression and in the entire population (50). The gene discussed is CD274; the disease is gastric cancer.